HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Non-Malignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide

Allogeneic hematopoietic cell transplantation (HCT) offers curative therapy for patients with non-malignant diseases, including primary immunodeficiencies, bone marrow failure syndromes, hemophagocytic disorders, metabolic disorders and hemoglobinopathies. Historically, myeloablative regimens have been used; however, this has been associated with increased risk for morbidity and mortality due to comorbidities as a result of their underlying disease. Therefore, less intense regimens are required.

https://www.bbmt.org/article/S1083-8791(20)30176-2/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - March 27, 2020 Category: Hematology Authors: Kanwaldeep K. Mallhi, Meera A. Srikanthan, Kelsey K. Baker, Haydar A. Frangoul, Troy R. Torgerson, Aleksandra Petrovic, Amy E. Geddis, Paul A. Carpenter, K. Scott Baker, Brenda M. Sandmaier, Monica S. Thakar, Suzanne Skoda-Smith, Hans-Peter Kiem, Rainer S Source Type: research